홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Isosorbide

HCID 12597
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
652-67-5
표준 SMILES
O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
InChIKey
KLDXJTOLSGUMSJ-JGWLITMVSA-N
분자식
C6H10O4
평균 분자량
146.14 g/mol
단동위원소 질량
146.0579088

개요

Isosorbide is an organic molecular entity.

이름 및 식별자

우선 이름
Isosorbide
IUPAC
(3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol
영어명
Isosorbide
분자식
C6H10O4
분자량
146.14

이름 및 동의어

isosorbide652-67-5IsobideDevicoran1,4:3,6-Dianhydro-D-glucitolHydronolIsmotic(3R,3aR,6S,6aR)-hexahydrofuro[3,2-b]furan-3,6-diol(+)-D-IsosorbideD-Glucitol, 1,4:3,6-dianhydro-1,4:3,6-Dianhydrosorbitol1,4:3,6-Dianhydro-D-sorbitol
이름 더 보기
at101Isosorbide (75% solution, 1 g)ucitoLIsosorbidNSC 40725
DTXSID5046196NSC-40725Glucitol, 1,4:3,6-dianhydro-, D-WXR179L51SNSC40725DTXCID3026196(3R,3aR,6S,6aR)-hexahydrofuro(3,2-b)furan-3,6-diolRefChem:55420

데이터베이스 식별자

CAS
652-67-5
PubChem CID
12597
DTXSID
DTXSID5046196
ChEMBL
CHEMBL1200660
ChEBI
CHEBI:6060
UNII
WXR179L51S
EC Number
211-492-3
Nikkaji
J7.077G

물성

구조 계산 물성

XLogP
-1.4
극성 표면적
58.9 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
4
회전 가능 결합 수
0
무거운 원자 수
10
형식 전하
0
복잡도
122

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Color/FormCRYSTALS
Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2건

60-63

61-64 °C

Food Contact SubstancesFCS -> FDA Cumulative Estimated Daily Intake (CEDI)
Optical RotationSPECIFIC OPTICAL ROTATION: +44 DEG/D
Physical DescriptionLiquid; Dry Powder; Liquid

물리화학적 성질

녹는점
60 · 60-63 °C (lit.)
끓는 점
175 °C/2mmHg · 175°C/2mmHg(lit.)
밀도
1.0945 · 1.0945 (rough estimate)
증기압
0.007 Pa · 0.007Pa at 20℃
굴절률
45 ° · 45 ° (C=5, H2O)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 3건

This chemical does not meet GHS hazard criteria for 99.3% (145 of 146) of all reports.

Not Classified

Aggregated GHS information provided per 146 reports by companies from 2 notifications to the ECHA C&L Inventory.

유해성 정보

Regulatory Information · 6건

Chemical: D-Glucitol, 1,4:3,6-dianhydro-

Regulation (EC) No 1935/2004 (amended)

D-Glucitol, 1,4:3,6-dianhydro- is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of D-Glucitol, 1,4:3,6-dianhydro- are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)

PMN - indicates a commenced PMN (Pre-Manufacture Notices) substance.

REACH registered substance: 1,4:3,6-dianhydro-D-glucitol (EC: 211-492-3)

D-Glucitol, 1,4:3,6-dianhydro-: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and CategoriesNot Classified

독성 정보

Adverse Effects · 1건

The adverse effects of isosorbide are due to the vasodilation of the venous capacitance vessels and the arterioles. The venodilation results in peripheral pooling of blood and arteriolar dilation, lowering systemic vascular resistance (afterload) and lowering blood pressure. Other adverse effects can be due to the reflex activity of the sympathetic nervous system due to vasodilation.

Toxicity Summary · 2건

IDENTIFICATION: Isosorbide dinitrate is a vasodilator, anti-anginal drug. Isosorbide dinitrate is a fine white to ivory-white odorless crystalline solid. It is sparingly soluble in water; freely soluble in acetone, chloroform, alcohol and ether. Indications: Isosorbide dinitrate is used principally in the management of patients with ischemic heart disease. It reduces the number, duration and severity of episodes of angina pectoris. Exercise tolerance is increased and the requirements for nitroglycerin are reduced. It is effective in all forms of angina, (stable effort angina, mixed angina, unstable angina and vasospastic or variant angina). It is used in acute myocardial infarction in control of ischemic pain, reduction of elevated blood pressure and in the treatment of pulmonary edema and congestive cardiac failure. It is also useful in the treatment of severe hypertension. The iv infusion can be used for precise control of blood pressure. It is used to control blood pressure during general anesthesia when precise control of blood pressure is important. It may also be used in esophageal spasm. HUMAN EXPOSURE: Main risks and target organs: Vasodilatation and hypotension (with their accompanying complications) are the main risks with overdose of isosorbide dinitrate. Heart and blood vessels are the target organs. Methemoglobinemia can occur. Summary of clinical effects: Features of poisoning may appear within few minutes to one hour or more after exposure. Tachycardia, hypotension followed by bradycardia and collapse, throbbing headache, dizziness, restlessness, syncope, convulsions and coma could occur. Some of the other features that can be seen include vomiting, diarrhea, cyanosis and methemoglobinemia. Respiratory failure may occur in severe cases. Clinical diagnosis is based on the history of exposure, and signs and symptoms observed: tachycardia, hypotension, throbbing headache, flushing of the face. Contraindications: Hypersensitivity to isosorbide dinitrate. Pre-existing methemoglobinemia. Marked anemia, head trauma or cerebral hemorrhage. Routes of entry: Oral: Oral entry and absorption through gastro-intestinal tract is the most frequent route of intoxication. Absorption can occur sublingually. Dermal: A preliminary report of experience with isosorbide dinitrate cream is available. Parenteral: Intoxication may occur in patients treated with intravenous isosorbide dinitrate. Absorption by route of exposure: Oral: Isosorbide dinitrate is readily absorbed from the oral mucosa and has a short duration of action. Following oral administration it is well absorbed from the gastrointestinal tract. In view of its first pass effect and short plasma half life, slow release formulations are available. Sublingual administration produces maximal concentration of the drug in plasma within 6 minutes. Dermal: Isosorbide dinitrate is also absorbed through the skin from an ointment base. The bioavailability of isosorbide dinitrate is about 29% following oral or sublingual dosing. Distribution by route of exposure: No data available. Biological half-life by route of exposure: The terminal elimination half-life of isosorbide dinitrate is 54.7 minutes, 48.8 minutes and 47.7 minutes respectively following IV injection, sublingual and oral administration. Metabolism: The major route of metabolism of isosorbide dinitrate in man is by enzymatic denitration followed by formation of glucuronides. The primary initial metabolites, isosorbide-2-mononitrate and isosorbide-5-mononitrate have longer half-lives (2-5 hours) and are presumed to be responsible, at least in part, for the therapeutic efficacy of isosorbide dinitrate. A substantial amount of drug can be metabolized due to the "first pass" effect. Elimination by route of exposure: Largely excreted in urine as isosorbide glucuronide. Mode of action: Toxicodynamics: Isosorbide dinitrate has dilator properties on vascular smooth muscle in virtually all vascular beds. Nitrates dilate veins, arteries, and, in high concentrations, arterioles. The beneficial effects in therapeutic doses and the effects seen with overdose are attributable to the physiologic consequences of systemic venous and arteriolar vasodilation. Cardiac preload, systemic blood pressure and systemic vascular resistance all show a progressive decrease. A state of hypotension, circulatory collapse and shock may result. Methemoglobinemia may occur following overdose of isosorbide dinitrate or during therapy. Pharmacodynamics: Organic nitrates can activate guanylate cyclase and increase the synthesis of guanosine 3', 5' - monophosphate (cyclic GMP) in smooth muscle and other tissues. The reactive free radical nitric oxide (NO) is formed which interacts with and activates guanylate cyclase. Interactions: Several important interactions may occur with other cardiovascular drugs. Severe postural hypotension has been observed in patients given isosorbide dinitrate and hydralazine for chronic cardiac failure.Undue dizziness and faintness may occur with sublingual nitrates and beta-adrenoceptor blocking drugs. Complete AV block has been reported after use of sublingual nitrates in patients receiving lignocaine by infusion. Even cardiac asystole may occur. Disopyramide, tricyclic antidepressants and other drugs with anticholinergic effects may prevent dissolution of sublingual isosorbide dinitrate tablets by causing dry mouth. The effects of acetylcholine, epinephrine and histamine can be antagonized by isosorbide dinitrate. An enhanced hypotensive effect may be seen with alcohol. Main adverse effects: The toxic effects of the nitrates are unaffected by the chemical form or by the route of administration and all the nitrates have a common profile of adverse effects. Hypotension, reflex tachycardia and palpitations may occur. Postural hypotension and syncope are seen, especially in elderly patients. Rarely severe bradycardia has been reported. Throbbing headache is quite common. This symptom is likely to recede as tolerance develops. Peripheral edema is also frequently seen. Transient hypoxaemia with precipitation of angina is seen occasionally. Transient cerebral ischemic episodes unrelated to changes in blood pressure are rarely seen. It is therefore advisable to initiate treatment with small doses in patients with cerebrovascular disease. Methemoglobinemia may be seen after therapeutic doses. Weakness, transient dizziness, restlessness and collapse may occur. Cutaneous flushing, perspiration and exfoliative dermatitis have all been reported. Nausea and vomiting are not frequent. Although tolerance has long been associated with nitrates, its clinical implications are not clear. Tolerance is best defined as a decreasing pharmacological effect over time, often with a need for an increasing dose to achieve a given action. Tolerance may be partial or complete and may occur with one type of nitrate therapy and not with others; disappearance of the throbbing headache is a useful sign. However, due to an attenuation of the antihypertensive effect, these agents are not useful in the long term management of hypertension. The part played by the arterial and venous sides of the circulation pertaining to the development of tolerance is not clear. By providing a long (approximately 8 hours) nitrate-free interval, the development of tolerance may be avoided or reduced. Decreasing the number of daily doses of isosorbide dinitrate also helps to achieve this effect. Sustained release preparations are more likely to produce tolerance than the short acting preparations. /Isosorbide dinitrate/

화학 및 산업

약리 정보

PharmacodynamicsIsosorbide reduces intraocular pressure through its effects on ocular blood vessels. While in the blood, isosorbide promotes redistribution of water toward the circulation, promoting the excretion of urine.
Mechanism of ActionIsosorbide causes vascular relaxation, reducing systolic ophthalmic artery pressure (SOAP), systolic ocular perfusion pressure (SOPP).
Biological Half-Life · 3건

TEN NORMAL MALES RECEIVED 0.25-1.5 G/KG ISOSORBIDE. DOSE RESPONSE EFFECTS ON WATER & OSMOLAR EXCRETION STATISTICALLY SIGNIFICANT. IN 9 VOLUNTEERS, ORALLY ADMIN ISOSORBIDE APPEARED RAPIDLY IN PLASMA & EXCRETED IN URINE WITH MEAN DISAPPEARANCE HALF-LIFE OF 8 HR.

ISOSORBIDE WAS RAPIDLY ABSORBED BY HUMANS FOLLOWING ORAL ADMIN & WAS EXCRETED UNCHANGED VIA KIDNEY WITH A MEAN DISAPPEARANCE T/2 OF APPROX 7 HR. IT INCREASED URINE VOLUME, CREATININE CLEARANCE, & SODIUM & CHLORIDE EXCRETION.

RABBITS GIVEN ORAL DOSES OF 2 G/KG FOR 1-7 DAYS HAD EST EXCRETION T/2 OF LESS THAN 6 HR IN ALL EYE TISSUE. PEAK LEVEL & EXCRETION T/2 WAS SIMILAR IN DAMAGED & UNDAMAGED EYE TISSUE, EXCEPT IN LENS OF DAMAGED EYES IN WHICH EXCRETION T/2 WAS SHORTER THAN OF NORMAL EYES.

MeSH Pharmacological ClassificationCompounds that increase urine volume by increasing the amount of osmotically active solute in the urine. Osmotic diuretics also increase the osmolarity of plasma.
Absorption, Distribution and Excretion · 2건

Isosorbide is rapidly absorbed after oral administration. Refer to [isosorbide mononitrate] for detailed absorption information.

IN DOGS, 5.5 MILLIMOLES/KG IV CAUSED LESS SOLUTE EXCRETION THAN AN EQUIMOLAR DOSE OF MANNITOL. THE DISTRIBUTION SPACE OF LABELED ISOSORBIDE WAS 54% OF BODY WT IN INTACT & NEPHRECTOMIZED DOGS. PROXIMAL TUBULAR REABSORPTION OF ISOSORBIDE WAS PROBABLY PASSIVE.

용도 및 제조

Uses · 2건

관련 반응

36건
반응 기록 만들기
HRID 29094 반응식
HRID 29094생성물로
HRID 61933 반응식
HRID 61933반응물로
HRID 336060 반응식
HRID 336060반응물로
HRID 462129 반응식
HRID 462129반응물로
HRID 462130 반응식
HRID 462130반응물로
HRID 485097 반응식
HRID 485097반응물로
HRID 542935 반응식
HRID 542935반응물로
HRID 542936 반응식
HRID 542936생성물로
이전1 / 5 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
저장 조건
Inert atmosphere,Room Temperature
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨), 물(약간 용해됨)
물리적 상태
결정, 결정질 고체 또는 질량
산도 계수 (pKa)
13.17 · 13.17±0.40(Predicted)
색상
황백색에서 연한 노란색 또는 베이지색
수용성
알코올, 물, 케톤에 용해됩니다.
Merck
14 · 14,5224
BRN
80510 · 80510
화장품 원료 기능
피부 컨디셔닝보습제
InChI
1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1
InChIKey
KLDXJTOLSGUMSJ-JGWLITMVSA-N
SMILES
O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12
LogP
-1.39 at · -1.39 at 20℃
EPA
1 · D-Glucitol, 1,4:3,6-dianhydro- (652-67-5)

화학적 성질

off-white to light yellow or beige crystals,

Isosorbide is relatively safe within the therapeutic range. The oral lethal dose LD50 of isosorbide is 2010 mg/kg in rats and 1771 mg/kg in mice. Lethal dose LD50 of isosorbide has not been a topic of sufficient research in the human population. The symptoms of isosorbide overdose may arise from its vasodilating property causing profound systemic hypotension, heart block with bradycardia, syncope, nausea, vomiting, increased intracranial tension (probably along with persistent throbbing headache, fever, confusion), diaphoresis, dizziness, and palpitations. There is limited clinical information available for the management of isosorbide overdose. The venous hypotension and the arterial hypovolemia of isosorbide overdose can be managed clinically by:

Human Toxicity Excerpts · 3건

UNTOWARD EFFECTS ARE...SIMILAR /TO GLYCERIN/, ALTHOUGH ISOSORBIDE DOES NOT ADVERSELY AFFECT BLOOD GLUCOSE LEVELS & MAY CAUSE LESS NAUSEA & VOMITING /ORAL ADMIN/.

USE OF ISOSORBIDE STUDIED IN 23 CHILDREN WITH MYELODYSPLASIA & HYDROCEPHALUS. REVERSIBLE MILD TOXICITY INCLUDED LOOSE STOOLS, PALLOR, IRRITABILITY, HYPERNATREMIA, & DOUGHY SKIN.

ISOSORBIDE ADMIN ORALLY IN DAILY DOSES AVG 10 G/KG FOR A MEAN DURATION OF 4 DAYS NOTED ELEVATED SERUM SODIUM OR BLOOD UREA NITROGEN LEVELS, AS OBSERVED IN 26 TRIALS. TOXICITY WAS ALWAYS REVERSED BY DOSAGE ADJUSTMENTS.

Drug Induced Liver Injury · 4건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Isosorbide

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

안전 데이터

wgk
2
tsca
TSCA listed
rtecs
LZ4380000
HS 번호
2934999090
risk_code
22
safety_code
24/25
기존화학 물질
KE-05-0437
스토리지 클래스
11 - Combustible Solids
유해 물질 데이터
652-67-5(Hazardous Substances Data)

MEDICATION

MEDICATION (VET)

U.S. Production2023: 80,993 lb
Consumer UsesNot Known or Reasonably Ascertainable
Industry UsesLubricating agent
Methods of ManufacturingPREPARED BY ACID DEHYDRATION OF D-GLUCITOL: HAWORTH, WIGGINS, BRITISH PATENT 600,870 (1948). PURIFICATION: HARTMANN, US PATENT 3,160,641 (1964 TO ATLAS CHEM INDUSTRIES).
Formulations/PreparationsISMOTIC (ALCON), ORAL AS 45% SOLUTION.
General Manufacturing Information · 3건

Plastics Material and Resin Manufacturing

D-Glucitol, 1,4:3,6-dianhydro-: ACTIVE

A POLYOL WITH HYDROXYL GROUP ATTACHED TO EACH OF TWO CIS-ORIENTED SATURATED FURAN RINGS.

응용 분야

용도Isosorbide is a reagent widely used to prepare detergents, cleansers, cosmetics, agrochemicals and vasodilators.

상·하류 제품 정보

상류 원료

D-소비톨D-솔비톨D-Glucitol, 3,6-anhydro-

하류 제품

이소소바드디메틸에테르D-Iditol, 2,5-anhydro-Hexitol, 2,5-anhydro-1.3.7-옥타트리엔테트라하이드로푸란2,2-Dimethyl-4-(2-oxiranyl)tetrahydrofuro[3,4-d][1,3]dioxole이소소르비드일질산염

추가 설명

정의A polyol with a hydroxyl group attached to each of two cis-oriented saturated furan rings. Intermediate for pharmaceuticals. Combustible.